acetyl l carnitine heart disease Frontiers Acetyl-L-Carnitine 500 mg

Advances in host-microbe metabolic axis

4) via comparing effects of fermented Chaga diet to that of nondiabetic age-matched control group

An LC-MS/MS method for simultaneous determination of three polygala saponin hydrolysates in rat plasma and its application to a pharmacokinetic study

The key findings were: Tirzepatide met the primary goal of cardiovascular non-inferiority , confirming it is at least as safe for the heart as dulaglutide It did not quite meet statistical superiority over dulaglutide for MACE, although results trended in favour of tirzepatide Tirzepatide produced significantly greater reductions in HbA1c and body weight than dulaglutide Importantly, because SURPASS-CVOT used an active comparator with established cardiovascular benefit rather than a placebo, demonstrating superiority was inherently more difficult than in earlier placebo-controlled GLP-1 outcome trials